Arcturus Therapeutics Files 8-K on Financials

TL;DR

ARCT filed an 8-K detailing financial results and operations.

AI Summary

Arcturus Therapeutics Holdings Inc. filed an 8-K on August 5, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 10628 Science Center Drive, Suite 250, San Diego, California.

Why It Matters

This filing provides crucial updates on Arcturus Therapeutics' financial health and operational performance, which are key indicators for investors and stakeholders.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not appear to contain any immediate material adverse information.

Key Players & Entities

• Arcturus Therapeutics Holdings Inc. (company) — Registrant
• August 5, 2024 (date) — Date of earliest event reported
• 10628 Science Center Drive, Suite 250, San Diego, California 92121 (address) — Principal executive offices
• 001-38942 (company_id) — SEC File Number

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share ARCT The Nasdaq Stock Mar

Filing Documents

• e663815_8k-arct.htm (8-K) — 28KB
• e663815_ex99-1.htm (EX-99.1) — 88KB
• 0001193805-24-000990.txt ( ) — 298KB
• arct-20240805.xsd (EX-101.SCH) — 3KB
• arct-20240805_lab.xml (EX-101.LAB) — 33KB
• arct-20240805_pre.xml (EX-101.PRE) — 22KB
• e663815_8k-arct_htm.xml (XML) — 4KB

02. Results of Operations and Financial Conditions

Item 2.02. Results of Operations and Financial Conditions. On August 5, 2024, Arcturus Therapeutics Holdings Inc. (the "Company" or "Arcturus") issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company's financial results for the quarter ended June 30, 2024 and providing a corporate update (the "Press Release"). The information contained in Item 2.02 of this Current Report on Form 8-K, including the Press Release, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference into any of the Company's filings with the Securities and Exchange Commission (the "SEC"), except as shall be expressly set forth by specific reference in any such filing. Cautionary Note Regarding Forward-Looking This Current Report on Form 8-K and the Press Release contain forward-looking Reform Act of 1995. Any statements, other than statements of historical fact included in this Current Report on Form 8-K and Press Release, are forward-looking statements, including those regarding strategy, future operations, the likelihood of success and continued advancement of the Company's pipeline (including ARCT-032 and ARCT-810) and partnered programs (including the COVID-19 and flu programs partnered with CSL Seqirus), the likelihood of commercialization of Kostaive and the timing thereof, the continued clinical development of the rare disease programs, the planned completion of the European Phase 2 ARCT-810 Phase 2 study and availability of interim data from the study, the likelihood and timing of a European Marketing Authorization application approval decisi

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Press Release dated August 5, 2024 104 Cover Page to this Current Report on Form 8-K in Inline XBRL

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arcturus Therapeutics Holdings Inc. Date: August 5, 2024 By: /s/ Joseph E. Payne Name: Joseph E. Payne Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR